Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes

S. M. Cabrera, S. C. Colvin, S. A. Tersey, Bernhard Maier, J. L. Nadler, Raghu Mirmira

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Summary: Type 1 diabetes (T1D) results from T helper type 1 (Th1)-mediated autoimmune destruction of insulin-producing β cells. Novel experimental therapies for T1D target immunomodulation, β cell survival and inflammation. We examined combination therapy with the dipeptidyl peptidase-IV inhibitor MK-626 and the histone deacetylase inhibitor vorinostat in the non-obese diabetic (NOD) mouse model of T1D. We hypothesized that combination therapy would ameliorate T1D by providing protection from β cell inflammatory destruction while simultaneously shifting the immune response towards immune-tolerizing regulatory T cells (Tregs). Although neither mono- nor combination therapies with MK-626 and vorinostat caused disease remission in diabetic NOD mice, the combination of MK-626 and vorinostat increased β cell area and reduced the mean insulitis score compared to diabetic control mice. In prediabetic NOD mice, MK-626 monotherapy resulted in improved glucose tolerance, a reduction in mean insulitis score and an increase in pancreatic lymph node Treg percentage, and combination therapy with MK-626 and vorinostat increased pancreatic lymph node Treg percentage. We conclude that neither single nor combination therapies using MK-626 and vorinostat induce diabetes remission in NOD mice, but combination therapy appears to have beneficial effects on β cell area, insulitis and Treg populations. Combinations of vorinostat and MK-626 may serve as beneficial adjunctive therapy in clinical trials for T1D prevention or remission.

Original languageEnglish
Pages (from-to)375-382
Number of pages8
JournalClinical and Experimental Immunology
Volume172
Issue number3
DOIs
StatePublished - Jun 2013

Fingerprint

Dipeptidyl Peptidase 4
Inbred NOD Mouse
Histone Deacetylase Inhibitors
Type 1 Diabetes Mellitus
Therapeutics
Lymph Nodes
Dipeptidyl-Peptidase IV Inhibitors
Investigational Therapies
Cytoprotection
Immunomodulation
Regulatory T-Lymphocytes
MK-626
vorinostat
Cell Survival
Clinical Trials
Insulin
Inflammation
Glucose

Keywords

  • Animal models (mice/rats)
  • Autoimmunity
  • Insulitis
  • Lymph nodes
  • Non-obese diabetic (NOD) mouse
  • Regulatory T cells
  • Type 1 diabetes

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes. / Cabrera, S. M.; Colvin, S. C.; Tersey, S. A.; Maier, Bernhard; Nadler, J. L.; Mirmira, Raghu.

In: Clinical and Experimental Immunology, Vol. 172, No. 3, 06.2013, p. 375-382.

Research output: Contribution to journalArticle

@article{d6071aa5801345419612e7bf027a6fc0,
title = "Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes",
abstract = "Summary: Type 1 diabetes (T1D) results from T helper type 1 (Th1)-mediated autoimmune destruction of insulin-producing β cells. Novel experimental therapies for T1D target immunomodulation, β cell survival and inflammation. We examined combination therapy with the dipeptidyl peptidase-IV inhibitor MK-626 and the histone deacetylase inhibitor vorinostat in the non-obese diabetic (NOD) mouse model of T1D. We hypothesized that combination therapy would ameliorate T1D by providing protection from β cell inflammatory destruction while simultaneously shifting the immune response towards immune-tolerizing regulatory T cells (Tregs). Although neither mono- nor combination therapies with MK-626 and vorinostat caused disease remission in diabetic NOD mice, the combination of MK-626 and vorinostat increased β cell area and reduced the mean insulitis score compared to diabetic control mice. In prediabetic NOD mice, MK-626 monotherapy resulted in improved glucose tolerance, a reduction in mean insulitis score and an increase in pancreatic lymph node Treg percentage, and combination therapy with MK-626 and vorinostat increased pancreatic lymph node Treg percentage. We conclude that neither single nor combination therapies using MK-626 and vorinostat induce diabetes remission in NOD mice, but combination therapy appears to have beneficial effects on β cell area, insulitis and Treg populations. Combinations of vorinostat and MK-626 may serve as beneficial adjunctive therapy in clinical trials for T1D prevention or remission.",
keywords = "Animal models (mice/rats), Autoimmunity, Insulitis, Lymph nodes, Non-obese diabetic (NOD) mouse, Regulatory T cells, Type 1 diabetes",
author = "Cabrera, {S. M.} and Colvin, {S. C.} and Tersey, {S. A.} and Bernhard Maier and Nadler, {J. L.} and Raghu Mirmira",
year = "2013",
month = "6",
doi = "10.1111/cei.12068",
language = "English",
volume = "172",
pages = "375--382",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes

AU - Cabrera, S. M.

AU - Colvin, S. C.

AU - Tersey, S. A.

AU - Maier, Bernhard

AU - Nadler, J. L.

AU - Mirmira, Raghu

PY - 2013/6

Y1 - 2013/6

N2 - Summary: Type 1 diabetes (T1D) results from T helper type 1 (Th1)-mediated autoimmune destruction of insulin-producing β cells. Novel experimental therapies for T1D target immunomodulation, β cell survival and inflammation. We examined combination therapy with the dipeptidyl peptidase-IV inhibitor MK-626 and the histone deacetylase inhibitor vorinostat in the non-obese diabetic (NOD) mouse model of T1D. We hypothesized that combination therapy would ameliorate T1D by providing protection from β cell inflammatory destruction while simultaneously shifting the immune response towards immune-tolerizing regulatory T cells (Tregs). Although neither mono- nor combination therapies with MK-626 and vorinostat caused disease remission in diabetic NOD mice, the combination of MK-626 and vorinostat increased β cell area and reduced the mean insulitis score compared to diabetic control mice. In prediabetic NOD mice, MK-626 monotherapy resulted in improved glucose tolerance, a reduction in mean insulitis score and an increase in pancreatic lymph node Treg percentage, and combination therapy with MK-626 and vorinostat increased pancreatic lymph node Treg percentage. We conclude that neither single nor combination therapies using MK-626 and vorinostat induce diabetes remission in NOD mice, but combination therapy appears to have beneficial effects on β cell area, insulitis and Treg populations. Combinations of vorinostat and MK-626 may serve as beneficial adjunctive therapy in clinical trials for T1D prevention or remission.

AB - Summary: Type 1 diabetes (T1D) results from T helper type 1 (Th1)-mediated autoimmune destruction of insulin-producing β cells. Novel experimental therapies for T1D target immunomodulation, β cell survival and inflammation. We examined combination therapy with the dipeptidyl peptidase-IV inhibitor MK-626 and the histone deacetylase inhibitor vorinostat in the non-obese diabetic (NOD) mouse model of T1D. We hypothesized that combination therapy would ameliorate T1D by providing protection from β cell inflammatory destruction while simultaneously shifting the immune response towards immune-tolerizing regulatory T cells (Tregs). Although neither mono- nor combination therapies with MK-626 and vorinostat caused disease remission in diabetic NOD mice, the combination of MK-626 and vorinostat increased β cell area and reduced the mean insulitis score compared to diabetic control mice. In prediabetic NOD mice, MK-626 monotherapy resulted in improved glucose tolerance, a reduction in mean insulitis score and an increase in pancreatic lymph node Treg percentage, and combination therapy with MK-626 and vorinostat increased pancreatic lymph node Treg percentage. We conclude that neither single nor combination therapies using MK-626 and vorinostat induce diabetes remission in NOD mice, but combination therapy appears to have beneficial effects on β cell area, insulitis and Treg populations. Combinations of vorinostat and MK-626 may serve as beneficial adjunctive therapy in clinical trials for T1D prevention or remission.

KW - Animal models (mice/rats)

KW - Autoimmunity

KW - Insulitis

KW - Lymph nodes

KW - Non-obese diabetic (NOD) mouse

KW - Regulatory T cells

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84876719833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876719833&partnerID=8YFLogxK

U2 - 10.1111/cei.12068

DO - 10.1111/cei.12068

M3 - Article

C2 - 23600825

AN - SCOPUS:84876719833

VL - 172

SP - 375

EP - 382

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -